Jason D. Davis Named CFO of FibroBiologics
Slice of Healthcare Team
06/11/2025
Key highlights
- Jason D. Davis, CPA, appointed Chief Financial Officer, effective immediately.
- Brings experience from Virax Biolabs, HyperDynamics Corp, and other public companies.
- Will support Phase 1/2 clinical trial for diabetic foot ulcers, set for H2 2025.
- Strengthens capital market strategy as company scales fibroblast-based therapies.
- Davis has led IPOs, capital raises, and SEC reporting throughout his career.
Notable Quotes
“ Jason brings exactly the kind of experience and leadership we need at this pivotal moment. His deep understanding of public company operations and capital markets isn’t just helpful — it’s a force multiplier as we move our lead program into the clinic. ”
Pete O’Heeron, Founder, Chairman and CEO at FibroBiologics, Inc
“ FibroBiologics, with its fibroblast-based platform, strong intellectual property portfolio, and well-defined clinical strategy, offers a truly differentiated approach to the development of therapeutics and potential cures for chronic diseases. ”
Jason D. Davis, Chief Financial Officer at FibroBiologics, Inc
Why This Matters
FibroBiologics’ appointment of Jason D. Davis signals a decisive move to align financial leadership with the company’s ambitious clinical roadmap. With over 275 patents and a unique fibroblast-based therapeutic approach, the company is poised for growth. Davis’ deep expertise in public company finance, IPOs, and capital raises is particularly vital as FibroBiologics prepares for its upcoming Phase 1/2 trial targeting diabetic foot ulcers—a serious chronic condition. His leadership is expected to enhance both operational execution and investor confidence during a crucial expansion phase.
